OrphaCare

OrphaCare is a specialized pharmaceutical company based in Vienna, Austria, that focuses on the development, licensing, and distribution of orphan drugs and therapies for intensive care and rare diseases. The company is best known for its portfolio of niche medical products, including Canemes (nabilone), which is used to treat chemotherapy-induced nausea and vomiting. In 2018, OrphaCare was acquired by AOP Orphan Pharmaceuticals (now AOP Health), a major European player in the rare and orphan disease space. This acquisition integrated OrphaCare's expertise in intensive care and oncology supportive care into AOP Health's broader commercial infrastructure. The company continues to serve specialized medical communities by providing access to essential therapies for patients with limited treatment options.